Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 9:00 AM ISTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial Medical Dialogues Bureau3 Nov 2019 9:00 AM ISTBristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study Medical Dialogues Bureau8 Sept 2019 9:15 AM ISTThe drug, Opdivo, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared...
Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel Medical Dialogues Bureau28 July 2019 9:17 AM ISTSales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene Medical Dialogues Bureau26 Jun 2019 9:00 AM ISTBristol-Myers announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
Exelixis drug improves overall survival in liver cancer patients Ruby Khatun Khatun21 Oct 2017 9:12 AM ISTExelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sept 2017 9:25 AM ISTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sept 2017 9:15 AM ISTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
Bristol-Myers stops kidney cancer drug test after early success Ruby Khatun Khatun11 Sept 2017 10:48 AM ISTBristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end...
